Almac Discusses New Biomarker Service on OutsourcingPharma.com
August 26, 2010
Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.
Click here to listen to podcast featuring Michael Sloan, VP Business Development (Almac’s Diagnostic Services division).
About Almac
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and technology (IVRS & Web), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 2,700 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $120m North American Headquarters started in July 2008 and will be completed 2010.
Almac’s Diagnostic Services division is a personalised medicine company focused on the discovery and development of biomarkers. They utilise their proprietary technology and extensive experience and expertise to offer solutions to biotech and Pharma partners. Almac focus on providing a range of services including exploratory biomarker discovery studies, verification studies for existing markers, assay development and biomarker validation.
For more information about the Almac Group, please visit almacgroup.com or e-mail [email protected].
Share